NPJ vaccines · 2026
Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vogel Annette B, Lui Bonny G, Tompkins Kristin, Kanevsky Isis, Muik Alexander, Krumm Stefanie A, Güler Alptekin, Maddur Mohan S, Walzer Kerstin C, Witzel Sonja, Vascotto Fulvia, Stanganello Eliana, Ota-Setlik Ayuko, Cottingham Kimberly J, Allbritton Omaira, Keverne Jessica, Aragão-Santiago Letícia, Swanson Kena A, Türeci Özlem, Şahin Uğur
Аннотация
We preclinically characterize BNT162b3, a nucleoside-modified mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding a trimerized, cell surface-tethered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD-foldon), formulated in lipid nanoparticles. Intramuscular immunization with BNT162b3 induced high antigen-specific antibody titers with early seroconversion kinetics in mice and rhesus macaques. One dose of BNT162b3 induced high neutralizing antibody titers against pseudoviruses harboring the spike of the SARS-CoV-2 Wuhan-Hu-1 strain and early variants of concern up to Delta, but lower titers against Omicron, the phylogenetically more distant variant. In mice, a second immunization boosted Omicron neutralizing antibody titers to levels comparable to those of other tested variants. The cellular immune response was T helper 1 cell driven. The cell surface-tethered RBD-foldon was more immunogenic than its soluble counterpart. This study demonstrated the suitability of BNT162b3 as COVID-19 vaccine and supported its evaluation in a phase I/II clinical trial (BNT162-04, NCT04537949).